Comments

Transcript

About this Series

Ovarian cancer is rare, and survival rates have seen only modest improvement in the past 40 years. But the number of women living with this cancer is now nearly 10 times its incidence, and this growing number of patients is ushering in a new age of research. Partnering with the exceptional women who are their patients, Dr Robert Coleman and the clinical team at MD Anderson are pioneering new trial designs at every stage of management. Taking on the challenges of delayed diagnosis, adjuvant therapy in advanced disease, and emerging therapies for recurrent disease, the MD Anderson team uses clinical trials to investigate treatment strategies that are giving oncologists and patients hope for improved outcomes in this challenging disease.

Show More

Who's Who
{{#each bp-whos-who.people}}
doc
●●●
{{{title}}}
{{{name}}} {{{addComma prof}}}
{{{desc}}}
{{#if disclosureTitle }} Disclosure
Disclosure
{{{disclosureTitle}}}
{{{disclosureText}}}
{{/if}}
More on Ovarian Cancer